Page 81 - HIV/AIDS Guidelines
P. 81

Table 7. Antiretroviral Components or Regimens Not Recommended as Initial Therapy



                   ARV drugs or components                Reasons for NOT recommending as initial therapy
                     (in alphabetical order)

             ABC/3TC/ZDV (coformulated) as triple-NRTI  • Inferior virologic efficacy
             combination regimen (BI)
             ABC + 3TC + ZDV + TDF as quadruple-NRTI  • Inferior virologic efficacy
             combination regimen (BI)

             DRV (unboosted)                        • Use without RTV has not been studied
             DLV (BIII)                             • Inferior virologic efficacy
                                                    • Inconvenient (three times daily) dosing
             ddI + 3TC (or FTC) (BIII)              • Inferior virologic efficacy
                                                    • Least clinical trial experience in ART-naive patients
             ddI + TDF (BII)                        • High rate of early virologic failure
                                                    • Rapid selection of resistance mutations
                                                    • Potential for immunologic nonresponse/CD4 T-cell decline
                                                    • Increased ddI drug exposure and toxicities
             T20 (BIII)                             • No clinical trial experience in ART-naive patients
                                                    • Requires twice-daily subcutaneous injections

             ETR (BIII)                             • Insufficient data in ART-naive patients
             FPV (unboosted) (BIII)                 • Less potent than RTV-boosted FPV
                                                    • Virologic failure with unboosted FPV-based regimen may select mutations
                                                     that confer resistance to DRV
             IDV (unboosted) (BIII)                 • Inconvenient dosing (three times daily with meal restrictions)
                                                    • Fluid requirement

             IDV (RTV-boosted) (BIII)               • High incidence of nephrolithiasis
             NFV (BI)                               • Inferior virologic efficacy
                                                    • High incidence of diarrhea
             RTV as sole PI (BIII)                  • High pill burden
                                                    • GI intolerance

             SQV (unboosted) (BI)                   • Inferior virologic efficacy
             d4T + 3TC (BI)                         • Significant toxicities including lipoatrophy; peripheral neuropathy; and
                                                     hyperlactatemia, including symptomatic and life-threatening lactic acidosis,
                                                     hepatic steatosis, and pancreatitis

             TPV (RTV-boosted) (BI)                 • Inferior virologic efficacy

            Key to Abbreviations: 3TC = lamivudine, ABC = abacavir, ART = antiretroviral therapy, ARV = antiretroviral, d4T = stavudine, ddI = didanosine,
            DLV = delavirdine, DRV = darunavir, ETR = etravirine, FPV = fosamprenavir, FTC = emtricitabine, GI = gastrointestinal, IDV = indinavir,
            NFV = nelfinavir, NRTI = nucleoside reverse transcriptase inhibitor, PI = protease inhibitor, RTV = ritonavir, SQV = saquinavir,
            T20 = enfuvirtide, TDF = tenofovir, TPV = tipranavir, ZDV = zidovudine






            Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents         F-20

                            Downloaded from http://aidsinfo.nih.gov/guidelines on 12/8/2012 EST.
   76   77   78   79   80   81   82   83   84   85   86